SAM
KDNY

Shell Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Shell Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,008
Closed -$118K – 1418
2022
Q3 		$118K Sell
6,008
-1,608
-21% -$32.3K ﹤0.01% 1172
2022
Q2 		$133K Buy
+7,616
New +$120K ﹤0.01% 1219

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Shell Asset Management's KDNY Position: Q4 2022 in Review

Shell Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2022, closing a stake of 6,008 shares — an estimated $118K sold.

Shell Asset Management first reported a position in KDNY in Q2 2022 and held it in 2 quarters. The position peaked at $133K in Q2 2022. 155 funds tracked by Wall St. Rank hold KDNY as of Q4 2022.

  • Shell Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Shell Asset Management sold 6,008 Chinook Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $118K.
  • Shell Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Shell Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $133K in Q2 2022.
  • 155 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Shell Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.